Compound Supply. 13 3.1.3 Screening Program Reports. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.2 Screening Supplies for Lead Optimization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.1 Supplies from Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.2 Shipping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.3 Limited Use. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.3
Compound Supply. Allelix shall, at its expense, supply to Aurora Compounds selected by Allelix for a Screening Program. In the event Allelix desires to have Aurora test in a Screening Program a Compound (including a library of compounds) owned, accessed or Controlled by Aurora, the parties agree to negotiate in good faith the terms and conditions under which such compound may be screened. Any compounds supplied by Allelix for use in a Screening Program will be provided to Aurora in 96-well microtiter plates, in the quantities, form and format as agreed by the CC. Aurora agrees not to transfer any compounds received from Allelix for use in connection with the Screening Program to any Third Party or to use such compounds for purposes not contemplated herein without Allelix's prior written consent.
Compound Supply. As soon as a Compound has been designated under the procedures of Section 3.2.3 above, the RMC shall convene to decide the most efficient route to produce sufficient quantities of such Compound, not to exceed [ * ] of such Compound, to give IBP the opportunity to perform the minimum studies required to determine IBP’s interest in obtaining a License to a Compound Set associated with such Compound. If the RMC determines that the most efficient route to make such Compound is via [ * ], the RMC shall so notify IBP in writing, and IBP shall be responsible for producing sufficient quantities of the Compound as reasonably specified by the RMC. However, if the RMC determines that the most efficient route to make such Compound is via [ * ], the RMC shall so notify Diversa in writing, and Diversa shall be responsible for producing and delivering to IBP sufficient quantities of the Compound via [ * ] as reasonably specified by the RMC. IBP shall have a maximum of [ * ] from manufacture or receipt (as applicable) of such applicable quantities of the Compound to carry out such studies. If, within such [ * ] period, IBP determines that such Compound is of interest to IBP, IBP shall promptly notify Diversa in writing as to IBP’s desire to obtain a License to such Compound Set associated with such Compound. Subject to the terms and conditions of this Agreement, upon such written notification, if such Compound is not an Excluded Compound at such time, Diversa shall be deemed to grant a License to the Compound Set with respect to such Compound and Products based thereon as provided in Section 4.1. If Diversa is not so notified within such [ * ] period, however, IBP shall thereafter have no right to License such Compound or the Compound Set with respect to such Compound.
Compound Supply. The Compound(s) generated hereunder shall be the sole and exclusive property of MERCK. PHARMATECH shall deliver to MERCK, * the requested amount, accompanied by a document, in English, describing the * to prepare each * and * to prove chemical identity and confirm overall *. MERCK shall have no obligation to accept or pay for any Compound(s) for which any of this data is not provided. PHARMATECH shall advise MERCK of all quantities of the Compound(s) generated hereunder in excess of the quantities requested by MERCK, which MERCK may agree to purchase at a mutually agreeable discounted price. If MERCK, in its sole discretion, decides not to purchase such additional quantities of any Compound(s), PHARMATECH agrees to dispose of such remaining quantities of the Compound(s), at its own cost and expense, according to instructions from MERCK. In no event shall PHARMATECH have any rights in or to any of the Compound(s) and PHARMATECH shall not retain any of the Compound(s) for its own purposes, or to use on behalf of any third party.
Compound Supply. Exscientia shall be responsible for the synthesis and supply to BMS of sufficient quantities of Licensed Compounds for the testing of Licensed Compounds in the performance of the Research Program in accordance with, and commensurate with the then-current stage of, the Research Plan. Upon request by BMS, Exscientia shall transfer to BMS Exscientia’s inventory of Licensed Compounds prepared by or for Exscientia in the conduct of the Research Program, provided that Exscientia shall retain that portion of such inventory required by Exscientia to fulfill its responsibilities under the Research Plan.
Compound Supply. XOMA(US) shall supply exclusively all of ALLERGAN's requirements of the Compound, in accordance with Section 2.7 below, to enable ALLERGAN to manufacture the Products. If XOMA(US) is unable to supply [*] of ALLERGAN's requirements of the Compound for more than ninety (90)days, ALLERGAN shall have the right to manufacture or purchase from Third Parties its requirement of Compound. XOMA(US) shall cooperate in obtaining such alternate supply source, including, without limitation, transferring such technology and know-how, and license rights as are reasonably necessary for ALLERGAN or a third party to manufacture Compound.
Compound Supply. (i) Tier 1. Roche represents and warrants that Exhibit F hereto contains a true and complete list of all existing (as of the Amendment Date) quantities of Tier 1 Program API, intermediates of such API, analytical markers and standards, drug product containing such API, placebo, and PET Ligand (collectively, “Tier 1 Materials”). Within thirty (30) days after the Amendment Date, Roche shall confirm the suitability for clinical use of such Tier 1 Materials by complete specification testing and issuance of a new Certificate of Analysis with an extended retest date, and shall supply all of such Tier 1 Materials (together all associated supporting documentation necessary for quality assessment or regulatory filings) to Synosia at no cost; provided, however, that Roche may retain such quantities of those Tier 1 Materials that are necessary for Roche to complete the Human Validation Study. Synosia shall not administer any such produced Tier 1 Materials to humans prior to testing and release of the same by Xxxxxxx.
Compound Supply. 4.01 During the term of this Agreement after completing the Development Activities and obtaining Governmental Approval according to Article 6, SENJU will supply to ISTA and ISTA will purchase the Compound from SENJU for commercial manufacture of the Product, as set forth in a separately executed supply agreement between SENJU and ISTA (hereinafter called “Supply Agreement”).
4.02 Separate from the Supply Agreement, [ * ]. The Parties shall discuss and decide the timing and delivery of the Compound supplied under this Paragraph 4.02.
4.03 SENJU shall acquire Compound from TANABE or TANABE’s contract manufacturer. SENJU represents to ISTA that SENJU has the exclusive right to supply the Compound for use in the Territory and agrees to exclusively supply ISTA Compound for use in the Territory. SENJU agrees and acknowledges that TANABE or TANABE’s contract manufacturer of the Compound shall have the U.S. FDA or other applicable governmental authority in the Territory make reference to the “Drug Master File” filed by TANABE or TANABE’s contract manufacturer for the sole purpose of obtaining Governmental Approval by ISTA in the Territory. SENJU shall have TANABE or TANABE’s contract manufacturer not withdraw or amend the “Drug Master File” without prior written approval of SENJU and ISTA. During the term hereof, SENJU shall ensure that it and its suppliers provide ISTA with a timely and dependable source of Compound to meet ISTA’s requirements therefor on commercially reasonable terms. ISTA shall have the right to perform, at its expense, reasonable quality audits of the facilities of SENJU, TANABE and TANABE’s contract manufacturer with respect to Compound supply during the term hereof.
4.04 The price of the Compound supplied by SENJU to ISTA under the Supply Agreement for manufacture of commercial Product will be at [ * ].
4.05 The Parties shall monitor market prices from Third Parties of the Compound. If at any time during the term of this Agreement, the price [ * ] of the Compound supplied by SENJU is [ * ] or more greater than the price [ * ] of the Compound available to ISTA from a Third Party, then SENJU shall [ * ].
Compound Supply. PD shall *** supply Aurora Compounds selected by PD for an Aurora Screening Program. In the event that PD desires to have Aurora test in an Aurora Screening Program a chemical (including a library of compounds) owned, accessed or Controlled by Aurora, the parties agree to negotiate in good faith the terms and conditions under which such compound may be screened. Any chemical supplied by PD for use in an Aurora Screening Program will be provided in 96-well microtiter plates, in quantities, form and format as agreed by the CSP Steering Committee ("Compound Supply"). Aurora agrees not to transfer the Compound Supply to any Third Party, attempt to analyze the Compound Supply for purposes of determining structure, or to use the Compound Supply for purposes not contemplated herein without PD's written consent. Aurora will return or destroy such Compound Supply upon written notice by PD.
Compound Supply. For the initial set of clinical trials in the Field in the Licensed Territory to be performed by Ocera under the License Agreement, Kureha shall manufacture and supply to Ocera a minimum of 120 kg of the Compound (the “Initial Supply”), and subsequently Kureha shall supply such additional amounts of the Compound as Ocera requests, based on the Forecasts (as defined below) and pursuant to purchase orders submitted pursuant to Section 3.1. Kureha will provide the Clinical Supply to Ocera in bulk quantities only; provided, however, that Kureha will provide the Clinical Supply to Ocera in packaged form upon Ocera’s request, subject to mutual agreement of the parties. Kureha agrees to enter into clinical manufacture and supply agreements, with economic and other fundamental terms substantially equivalent to the terms herein, with Sublicensees.
